WO2008096369A3 - Pharmaceutical formulation for use in hiv therapy - Google Patents

Pharmaceutical formulation for use in hiv therapy Download PDF

Info

Publication number
WO2008096369A3
WO2008096369A3 PCT/IN2008/000068 IN2008000068W WO2008096369A3 WO 2008096369 A3 WO2008096369 A3 WO 2008096369A3 IN 2008000068 W IN2008000068 W IN 2008000068W WO 2008096369 A3 WO2008096369 A3 WO 2008096369A3
Authority
WO
WIPO (PCT)
Prior art keywords
reverse transcriptase
pharmaceutical formulation
transcriptase inhibitors
analog reverse
hiv therapy
Prior art date
Application number
PCT/IN2008/000068
Other languages
French (fr)
Other versions
WO2008096369A2 (en
Inventor
Neha Shesh Wyawahare
Ramesh A
Mahesh Mohanrao Bhadgale
Abhijit Mukund Deshmukh
Sanjeev Meharchand Sethi
Kumar Shanmugham
Prakash Balakrishna Shetiya
Chetan Murthy Rajashekara
Original Assignee
Matrix Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Limited filed Critical Matrix Laboratories Limited
Publication of WO2008096369A2 publication Critical patent/WO2008096369A2/en
Publication of WO2008096369A3 publication Critical patent/WO2008096369A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A monolithic tablet formulation comprising: a) a nucleotide analog reverse transcriptase inhibitor (NtRTI); b) a non-nucleoside reverse transcriptase inhibitors (NNRTI); c) a nucleoside analog reverse transcriptase inhibitors (NRTI) and d) one or more pharmaceutically acceptable carriers or excipients. Also disclosed is another pharmaceutical formulation comprising: a) nucleotide analog reverse transcriptase inhibitors (NtRTIs); b) nucleoside analog reverse transcriptase inhibitors (NRTIs) and d) one or more pharmaceutically acceptable carriers or excipients.
PCT/IN2008/000068 2007-02-05 2008-02-04 Pharmaceutical formulation for use in hiv therapy WO2008096369A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN257CH2007 2007-02-05
IN257/CHE/2007 2007-02-05

Publications (2)

Publication Number Publication Date
WO2008096369A2 WO2008096369A2 (en) 2008-08-14
WO2008096369A3 true WO2008096369A3 (en) 2009-12-30

Family

ID=39682191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000068 WO2008096369A2 (en) 2007-02-05 2008-02-04 Pharmaceutical formulation for use in hiv therapy

Country Status (1)

Country Link
WO (1) WO2008096369A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009106954A1 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable dosage forms of lamivudine and tenofovir
WO2009106960A2 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
CN103211826A (en) * 2013-05-14 2013-07-24 福建广生堂药业股份有限公司 Antiviral pharmaceutical composition as well as preparation method and application thereof
JP2016528240A (en) * 2013-08-14 2016-09-15 ラシオファルム ゲーエムベーハー Medicament having a medicinal combination of doltegravir, emtricitabine and tenofovir
IN2013CH05288A (en) * 2013-11-18 2015-09-11 Aurobindo Pharma Ltd
CZ2013985A3 (en) * 2013-12-09 2015-06-17 Zentiva, K.S. Stable pharmaceutical composition containing tenofovir disoproxil fumarate
TR201617448A2 (en) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TENOFOVIR AND EMTRISITAB
CN106822155B (en) * 2016-12-29 2019-10-11 东北制药集团股份有限公司 Piece and preparation method thereof in three Compound Tablet of efavirenz, Lamivudine and tenofovir disoproxil fumarate
TR201713954A2 (en) * 2017-09-20 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRISITABIN AND EAVIRENZINE
JP2023503903A (en) * 2019-11-26 2023-02-01 バイオトロン リミティッド Methods of treating HIV-1 infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064845A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20060194272A1 (en) * 2005-02-25 2006-08-31 Sysmex Corporation Reference material for assaying D-dimer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064845A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20060194272A1 (en) * 2005-02-25 2006-08-31 Sysmex Corporation Reference material for assaying D-dimer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIEBERT., ANTIVIRAL BRIEFS. AIDS PATIENT CARE AND STDS, vol. 20, no. 12, December 2006 (2006-12-01), pages 887 - 889 *
NIAZI.: "Handbook of Pharmaceutical Manufacturing Formulations: Compressed solid products", 2004, INFORMA HEALTH CARE, pages: 21,47,53 *

Also Published As

Publication number Publication date
WO2008096369A2 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
WO2008096369A3 (en) Pharmaceutical formulation for use in hiv therapy
WO2007068934A3 (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
WO2008146178A3 (en) A novel tablet dosage form
NO20092636L (en) Non-nucleoside reverse transcriptase inhibitors
WO2014078778A3 (en) Antiviral azasugar-containing nucleosides
MX2020007625A (en) Mtor inhibitor, pharmaceutical composition and use thereof.
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2007015812A3 (en) Hiv reverse transcriptase inhibitors
EP1564210A4 (en) 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
EP2033954A4 (en) 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor
IL200561A (en) Heterocyclic aspartyl protease inhibitors or tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same and use thereof
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
DK1636236T3 (en) Pyrazolo-quinazoline derivatives, a process for their preparation, and their use as kinase inhibitors
PL1727551T3 (en) Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
HK1098372A1 (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007146230A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
SG10201903619YA (en) Carbazole derivatives
ZA200706306B (en) Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
WO2007087188A8 (en) Taste-masked tablets and granules
WO2004034962A3 (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
WO2010081722A3 (en) Orally disintegrating tablets for the treatment of pain
EP1909804A4 (en) Glucosamine and derivatives thereof useful as tg inhibitors
AR038858A1 (en) COMBINATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08738359

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08738359

Country of ref document: EP

Kind code of ref document: A2